Company Long-Term Loans and Borrowings: REGENXBIO Inc (RGNX)

Brandmark of Regenxbio (RGNX)

REGENXBIO Inc. (RGNX) relies on its proprietary gene therapy delivery system, monetizing exclusive vector rights through external contracts. Multi-year royalty agreements with global pharma behemoths ensure business stability. The current figure is 0.28. The asset's price trajectory on the GURU.Markets platform may be subject to adjustments due to the complexity of international research and risks associated with biomaterial logistics disruptions.

REGENXBIO Inc. (RGNX) Company Long-Term Debts: for the period 07/04/2022 - 10/31/2026

Summary analytical data breakdowns for Regenxbio (RGNX)

- market price and analyst price targets:
Stock Price regenxbio.com|RGNX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value REGENXBIO|RGNX - Enterprise Value
- book capitalization information:
Net Asset Value per Share REGENXBIO|RGNX - Book Capitalization|Market Value to Equity Ratio regenxbio.com|RGNX - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital REGENXBIO Inc.|RGNX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio REGENXBIO Corp|RGNX - Company Total Debt|Debt to Book Value Ratio REGENXBIO|RGNX - Company Long-Term Debts|Company Short-Term Debt REGENXBIO|Interim Coverage Ratio regenxbio.com
- earnings and market multiples details:
RGNX - Company Net Income
Fundamental company valuation:regenxbio.com - RGNX
Manufactured product of regenxbio.com

Long-term debt measures the total liabilities with a maturity of more than one year, determining the issuer's financial autonomy and default risk. For REGENXBIO Inc. (RGNX), this metric reflects the cost of scaling the NAV platform and clinical trial expenses. Assessing the corporation's long-term loans and borrowings on GURU.Markets allows for a comparison of the debt load against the effectiveness of attracting strategic partners. Stable borrowing trends confirm the resilience of the gene therapy business model.

Who REGENXBIO Inc. competes with

Company Long-Term Debts Tempus Labs TEM|QGEN - Company Long-Term Debt|Company Long-Term Loans and Borrowings IONS (Ionis Pharmaceuticals, Inc.)|RGEN: Company Long-Term Debts|Long-Term Debt Avidity Corp (RNA)|CRSP (CRISPR Therapeutics AG) - Company Long-Term Debts|WGS - Long-Term Indebtedness|Company Long-Term Debts RARE|BEAM - Long-Term Debt|Company Long-Term Debt Sarepta Therapeutics Inc SRPT|TWST: Company Long-Term Indebtedness|TXG: Company Long-Term Liabilities|NTLA (intelliatx.com) - Company Long-Term Indebtedness|STOK: Company Long-Term Debts|BLFS (BioLife Solutions Inc) - Company Long-Term Debt|WVE (Wave Life Sciences Corp) - Company Long-Term Debts|Maze Therapeutics Corp (MAZE) - Long-Term Debt Volume|Company Long-Term Debt Sionna Therapeutics Inc (SION)|PRME - Long-Term Debt|Taysha Gene Therapies, Inc. - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings QURE|MeiraGTx PLC - Company Long-Term Debts|Long-Term Debt Volume Solid Corp SLDB|Ocugen, Inc. (OCGN) - Company Long-Term Debt|Company Long-Term Indebtedness PACB|BNTC (Benitec Biopharma) - Company Long-Term Debts|Company Long-Term Liabilities Design Therapeutics Inc (DSGN)|Company Long-Term Liabilities RCKT (Rocket Pharmaceuticals Inc)|Long-Term Debt Volume 4D Molecular Corp|Company Long-Term Debt Lexeo Therapeutics, Inc. LXEO|Company Long-Term Loans and Borrowings KRRO|Editas Medicine - Company Long-Term Debts|Long-Term Indebtedness Silence Therapeutics PLC (SLN)|proqr.com (PRQR) - Company Long-Term Debt|Company Long-Term Indebtedness CDXS|Company Long-Term Liabilities SGMO|Company Long-Term Indebtedness NAUT (Nautilus Biotechnology Inc)|Company Long-Term Debts MGX|Precision BioSciences Inc. - Company Long-Term Indebtedness|Company Long-Term Debt Generation Bio GBIO|BOLD: Company Long-Term Indebtedness|Exicure Corp - Company Long-Term Debts|IMNN - Company Long-Term Debts|phiopharma.com (PHIO) - Company Long-Term Debt|Mustang Bio - Company Long-Term Loans and Borrowings|RNAZ (TransCode Therapeutics Inc.) - Company Long-Term Debts|Long-Term Debt Bionano BNGO|Company Long-Term Debts APDN|bluebirdbio.com (BLUE) - Long-Term Indebtedness|Company Long-Term Debts IPA (ImmunoPrecise Antibodies Ltd.)|Omega Therapeutics Inc (OMGA) - Long-Term Debt|OMIC - Company Long-Term Debt|RGLS (Regulus) - Company Long-Term Indebtedness|SYRS (Syros Pharmaceuticals) - Company Long-Term Liabilities|Company Long-Term Indebtedness TBIO|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Company Long-Term Debt UBX